HAL Allergy Group

Updated on Dec 14, 2023

Edit

Comment

Industry Pharmaceutical Products PURETHAL, SUBLIVAC Headquarters Leiden Number of employees 300		Founder Dr. Johan Kuijper Website www.hal-allergy.com Founded 1959 Type of business Private

Hal allergy group dr harry flore ceo

HAL Allergy Group is a pharmaceutical company that develops, produces and sells products for allergy diagnostic and Allergen immunotherapy (AIT). The research facilities are located in Leiden Bio Science Park, Netherlands.

The focus since 1959 stems from the development, production and distribution of Allergen Immunotherapies for the treatment and prevention of allergic diseases. These immunotherapies are used primarily against common allergies such as hay fever, house dust mite allergy and allergic reactions towards wasp or bee stings. With offices in major European countries, HAL Allergy is one of the European top players, particularly in the field of allergy.

In addition, HAL Allergy has a specific expertise in the area of contract manufacturing with focus on the production of biopharmaceutical products for preclinical and clinical studies. This is done by its subsidiary HALIX B.V.

HAL Allergy originally stems from 'Haarlems Allergenen Laboratorium', a Dutch company set up in Haarlem. The company started as a small laboratory where, on request of several local general practitioners (GPs), extracts were prepared on a named patient basis to treat against allergic reactions.

Halix contract manufacturing organization cmo of hal allergy group

History

HAL Allergy was established in 1959. At the time of its inception it was located in the centre of Haarlem. The name HAL Allergy comes from 'Haarlems Allergenen Laboratorium'.

The founder of HAL Allergy Dr. Johan Kuijper identified at an early stage the relevance of standardisation and stability of allergen extracts as well as being one of the initiators of the establishment of a European Clearing House for allergen extracts from which the Paul Ehrlich Seminars originated.

In the 1970s, the company began exporting to Germany on larger scale. Over the years, the product portfolio has seen changes and development. In January 2007 the company moved from Haarlem to bigger premises at the Bio Science Park in Leiden in the Netherlands

Aside from the development and production of allergy vaccines HAL Allergy started a Contract Manufacturing Organization (CMO) in 2012, named HALIX that is engaged in the production of biotechnological products for preclinical and clinical studies.

Timeline

1959: Foundation of HAL Allergy (Haarlems Allergenen Laboratorium BV)

1965: Production of the first standard series of allergens for epicutaneous testing

1966: Introduction of the first commercially available house-dust mite extract by HAL Introduction of the biological standardization for allergen activity determination for each batch

1969: Introduction of aluminium hydroxide depot extracts

1974: Introduction of HAL ORAL

1977: Introduction of product for the diagnosis of type III-allergies; Start operations of HAL Allergy in Germany

1980: HALISA - the HAL-ELISA for type III-allergy diagnosis - is introduced

1982: HAL allergen extracts are stabilized by Epsilon Amino Caproic Acid (EACA)

1986: Introduction of Grasses (allergoid glutaraldehyde modified depot extracts)

1988: Standardization of allergen extracts in Allergy Units (A.U.), according to the FDA standardization

1990: Introduction of PURETHAL Birch and ACTI.TIP system for type I-allergy

1995: Introduction of SUBLIVAC B.E.S.T. sublingual immunotherapy

1998: Introduction of VENOMENHAL Bee and Wasp Venoms

1999: Extension of the PURETHAL product range

2000: Start operations of HAL Allergy in Poland

2001: Start operations of HAL Allergy in Austria; Introduction of PURETHAL Mites

2003: Start operations of HAL Allergy in Italy

2005: Start operations of HAL Allergy in Spain

2008: Introduction of PURETHAL / SUBLIVAC® one bottle

2009: Opening new GMP facilities in Leiden Introduction of SUBLIVAL FIX

2011: Introduction of PURETHAL RUSH Scheme Grasses

2012: Start HALIX Contract Manufacturing Organization

2014: Introduction of PURETHAL RUSH Scheme Birch

Corporate information

HAL Allergy is a privately held company registered in The Netherlands. HAL Allergy is a part of Droege International Group AG.

The members of HAL Allergy's board of directors are:

Dr. Harry Flore: Chief Executive Officer

Dr. Tomasz P. Bednarczyk: Chief Commercial & Financial Officer

Research

HAL Allergy develops and markets innovative products, that are convenient-to-use, for the treatment of respiratory, venom and food allergies.

In 2016: HAL Allergy has successfully completed the First-In-Human study with their subcutaneous immunotherapeutic drug for peanut allergy.

In 2016: HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy.

Products

Allergy immunotherapy products account for most of HAL Allergy's ’s revenues and comprise the following types of product:

Sublingual immunotherapy (SLIT). A droplet-based allergy vaccine marketed under various brand names including SUBLIVAC and covering various allergens and combinations of allergens, including pollens, molds, mites and pets.

Subcutaneous immunotherapy (SCIT). An injection-based allergy vaccine marketed under various brand names including PURETHAL, VENOMENHAL and covering the most common allergens such as pollens, molds, mites, pets, bees and wasps.

The aforementioned allergy immunotherapy products are purified from natural sources.

Sponsorships

HAL Allergy is one of the founder sponsors of the European Academy of Allergy and Clinical Immunology (EAACI).

References

HAL Allergy Group Wikipedia

(Text) CC BY-SA